Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam

Neuropsychopharmacology

Volumn 16, Issue 1, 1997, Pages 8-14

  Otani, Koichi ^a   Yasui, Norio ^a   Kaneko, Sunao ^a   Ohkubo, Tadashi ^a   Osanai, Takako ^b   Sugawara, Kazunobu ^a   Hayashi, Kunihiko ^c   Chiba, Kan ^d   Ishizaki, Takashi ^d  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Goshogawara City Hospital   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Alprazolam; Cytochrome P450 (CYP) isoforms; Metabolism; S mephenytoin 4 hydroxylation; Smoking

Indexed keywords

ALPRAZOLAM; MEPHENYTOIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHENOTYPE; PRIORITY JOURNAL; SMOKING;

EID: 0031027690     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00165-0     Document Type: Article

References (33)

1. Alván G, Bechtel P, Iselius L, Gundert-Remy U (1990): Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537
2. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P (1990): Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47:79-85
3. Bertilsson L, Aberg-Wistedt A, Liden A, Otani K, Spina E (1988): Alprazolam does not inhibit the metabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. Ther Drug Monit 10:231-233
4. Bertilsson L, Henthorn T, Sanz E, Tybring G, Säwe J, Villén T (1989): Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355
5. Bock KW, Schrenk D, Forster A, Griese E-U, Morike K, Brockmeier D, Eichelbaum M (1994): The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyl transferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-228
6. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993): Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214
7. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T (1993): Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther 266:52-59
8. Chiba K, Saitoh, Koyame E, Tani M, Hayashi M, Ishizaki T (1994): The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 37:237-242
9. Dahl M-L, Bertilsson L (1993): Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3:61-70
10. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994): The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422
11. Fleishaker JC, Hulst LK (1994): A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35-39
12. Friedman H, Redmond DE, Greenblatt DJ (1991): Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African green monkeys. Psychopharmacology 104:103-105
13. Goldstein JA, de Morais MF (1994): Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299
14. Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J (1977): Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatr 134: 559-562
15. Greenblatt DJ, Wright CE (1993): Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 24:453-471
16. Gugler R, Jensen JC (1985): Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89:1235-1241
17. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, Liao C-L, Zhang L-M (1989): Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207
18. Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T (1995): Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther 58:155-164
19. Koyama E, Sohn D-R, Shin S-G, Chiba K, Shin J-G, Kim Y-H, Echizen H, Ishizaki T (1994): Metabolic disposition of imipramine in Oriental subjects: Relation to metoprolol α-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. J Pharmacol Exp Ther 271:860-867
20. Küpfer A, Preisig R (1984): Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:743-749
21. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987): The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76(suppl 334):11-100
22. Rasmussen B, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K (1995): Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151-159
23. Rowland M, Tozer TN (1995): Clinical Pharmokinetics. Concepts and Applications, 3d ed., Baltimore, Williams & Wilkins
24. Smith RB, Gwilt PR, Wright E (1983): Single-and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharm 2:139-143
25. Sohn D - R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T (1992b): Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 262:1195-1202
26. Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Chiba K (1992a): Incidence of S-mephenytoin hydroxylation deficiency in Korean population and the interphenotypic dif-ferences in diazepam pharmacokinetics. Clin Pharmacol Ther 52:160-169
27. Spina E, Caputi A (1994): Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications. Pharmacol Res 29:121-137
28. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994): Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31
29. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995): Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131
30. Watkins PB (1994): Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184
31. Wilkinson GR, Guengerich FP, Branch RA (1989): Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53-76
32. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y (1995): Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 17:333-335
33. Zar JH (1996): Biostatistical Analysis, 3d ed., Upper Saddle River, NJ, Prentice-Hall